They estimate that 67% of human HNSCC patients have NOTCH pathway inactivation—including about 27% with inactivating NOTCH1/2/3 mutations and about 40% with inactivating alterations of ADAM10, RIPK4, or AJUBA or amplification of NUMB, an AJUBA interactor. The gene discussed is NOTCH1; the disease is head and neck squamous cell carcinoma.